Pfizer Inc (PFE) 36.30 $PFE
Pfizer (PFE) Approaches New Upside Target of $36.46
Comtex SmarTrend(R) - Wed Jul 13, 9:07AM CDT
Shares of Pfizer (NYSE
FE) have bullishly opened above the pivot of $36.19 today and have reached the first resistance level of $36.34. Investors may be interested in a cross of the next upside pivot targets of $36.46 and $36.73.
PFE: 36.30 (+0.06)
Pfizer (PFE) Gets FDA Nod for Label Expansion of Prevnar 13
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 8:25AM CDT
Pfizer Inc. (PFE) announced that the FDA has approved a label expansion of vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).
ABT: 42.01 (-0.46), JNJ: 122.89 (-0.03), PFE: 36.30 (+0.06)
The New #22 Most Shorted Dow Component: Pfizer
MarketNewsVideo.com - Wed Jul 13, 8:19AM CDT
The most recent short interest data has been released for the 06/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover."...
PFE: 36.30 (+0.06)
Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis
BusinessWire - Wed Jul 13, 7:00AM CDT
Pfizer Inc. (NYSEFE) announced today the publication of findings from two pivotal Phase 3 studies of investigational crisaborole topical ointment 2% (formerly AN2728) in the online issue of the Journal of the American Academy of Dermatology.
PFE: 36.30 (+0.06)
Sucampo to Stop Developing Cobiprostone for Oral Mucositis
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:28PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) announced that it will discontinue the development of its pipeline candidate, cobiprostone.
JNJ: 122.89 (-0.03), PFE: 36.30 (+0.06), SCMP: 11.37 (+0.04)
Shire's (SHPG) Dry Eye Disease Drug Xiidra Gets FDA Nod
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:20PM CDT
Shire plc (SHPG) received a major boost when the FDA approved its ophthalmology drug Xiidra for the treatment of the signs and symptoms of dry eye disease in adults.
JNJ: 122.89 (-0.03), SHPG: 193.07 (-2.24), PFE: 36.30 (+0.06)
Lower-cost biotech drug gets thumbs up from FDA panel
By MATTHEW PERRONE - AP - Tue Jul 12, 4:39PM CDT
WASHINGTON (AP) — The second-biggest selling drug in the world could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat rheumatoid arthritis and other inflammatory diseases.
JNJ: 122.89 (-0.03), PFE: 36.30 (+0.06), AMGN: 160.90 (-1.06)
JNJ VS. PFE: Which Is The Better Large Cap Pharma Stock?
Adam Clark - Zacks Investment Research - Mon Jul 11, 12:06PM CDT
Operating in an industry ranked in the top 10% of all industries by Zacks and both stocks sporting a Zacks Rank #2 (Buy), Johnson&Johnson and Pfizer Inc. should both be getting looked at from investors right now, but which is the better buy?
JNJ: 122.89 (-0.03), PFE: 36.30 (+0.06)
Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:23AM CDT
Pfizer Inc. (PFE) announced positive results from the phase III study, S-TRAC, on kidney cancer drug Sutent.
ABT: 42.01 (-0.46), PFE: 36.30 (+0.06), EXEL: 8.13 (-0.01), NVS: 82.08 (+0.40)
Shire (SHPG) Gets EU Nod for Label Expansion of Revestive
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:36PM CDT
Shire plc (SHPG) announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population.
ABT: 42.01 (-0.46), JNJ: 122.89 (-0.03), SHPG: 193.07 (-2.24), PFE: 36.30 (+0.06)
Roche Asthma Drug Xolair Gets FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:23PM CDT
Roche Holding AG (RHHBY) announced that the FDA has approved a label expansion of respiratory drug, Xolair.
JNJ: 122.89 (-0.03), PFE: 36.30 (+0.06), NVS: 82.08 (+0.40)
Alnylam (ALNY) Begins Phase I/II Study on Chronic HBV Drug
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 10:34AM CDT
Alnylam Pharmaceuticals (ALNY) announced that it has started a phase I/II study on ALN-HBV for the treatment of chronic hepatitis B virus infection.
ALNY: 63.19 (-0.81), INVA: 11.89 (+0.13), PFE: 36.30 (+0.06), BMY: 76.71 (+0.51)
Puma (PBYI) Stock Up, Phase II Data on Neratinib Published
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 10:28AM CDT
Puma Biotechnology (PBYI) reported the publication of phase II study (I-SPY 2) data on neratinib for the neoadjuvant treatment of breast cancer.
INVA: 11.89 (+0.13), PFE: 36.30 (+0.06), PBYI: 32.72 (-1.44)
Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT(R) (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma
BusinessWire - Fri Jul 08, 7:00AM CDT
Pfizer Inc. (NYSEFE) today announced that the S-TRAC clinical trial (Sunitinib Trial in Adjuvant Renal Cancer), a Phase 3 study of SUTENT versus placebo in the adjuvant setting, met its primary endpoint of improving disease-free survival (DFS) as determined by blinded independent central review in patients with renal cell carcinoma (RCC) who are at high risk for recurrence after surgery. The S-TRAC trial is the first RCC trial of a tyrosine kinase inhibitor (TKI) to prolong DFS in the adjuvant setting. The concept of adjuvant therapy is to help lower the risk of cancer recurrence in patients with early-stage cancer.
PFE: 36.30 (+0.06)
Seattle Genetics/Takeda Adectris' Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:21PM CDT
Seattle Genetics, Inc. (SGEN) announced that its partner Takeda Pharmaceutical Company Limited (TKPYY) has received marketing authorization for the label expansion of its lymphoma drug, Adcetris.
JNJ: 122.89 (-0.03), SGEN: 41.45 (-1.09), PFE: 36.30 (+0.06)
Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:54PM CDT
Merck (MKGAF) and Pfizer (PFE) initiated JAVELIN Ovarian 100 on avelumab, in combination with platinum-based chemotherapy, for the treatment of ovarian cancer.
GWPH: 92.58 (-4.52), UTHR: 109.87 (-3.06), PFE: 36.30 (+0.06)
Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:09AM CDT
Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.
INVA: 11.89 (+0.13), PFE: 36.30 (+0.06), SNY: 42.04 (-0.46), REGN: 366.21 (-2.54)
Bristol-Myers Buys Cormorant, Focus on Immuno-Oncology
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:02AM CDT
Bristol-Myers (BMY) acquires a privately held pharma company, Cormorant Pharmaceuticals, to bolster its immuno-oncology pipeline.
INVA: 11.89 (+0.13), PFE: 36.30 (+0.06), BMY: 76.71 (+0.51)
Abbott Labs' Absorb Stent Gets Regulatory Approval in U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:58AM CDT
Abbott Laboratories (ABT) received a major boost when the FDA approved its bioresorbable heart stent, Absorb, for the treatment of coronary artery disease in the U.S.
ABT: 42.01 (-0.46), JNJ: 122.89 (-0.03), PFE: 36.30 (+0.06), STJ: 80.62 (-0.26)
Pfizer agrees to note addiction risks in opioid marketing
By JASON KEYSER - AP - Wed Jul 06, 1:48PM CDT
CHICAGO (AP) — The city of Chicago and Pfizer announced an agreement Wednesday committing the drugmaker to disclosing the serious risks of addiction in its marketing of prescription opioid painkillers.
PFE: 36.30 (+0.06)
Pfizer (PFE) Approaches New Upside Target of $36.46
Comtex SmarTrend(R) - Wed Jul 13, 9:07AM CDT
Shares of Pfizer (NYSE
FE) have bullishly opened above the pivot of $36.19 today and have reached the first resistance level of $36.34. Investors may be interested in a cross of the next upside pivot targets of $36.46 and $36.73. PFE: 36.30 (+0.06)
Pfizer (PFE) Gets FDA Nod for Label Expansion of Prevnar 13
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 8:25AM CDT
Pfizer Inc. (PFE) announced that the FDA has approved a label expansion of vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).
ABT: 42.01 (-0.46), JNJ: 122.89 (-0.03), PFE: 36.30 (+0.06)
The New #22 Most Shorted Dow Component: Pfizer
MarketNewsVideo.com - Wed Jul 13, 8:19AM CDT
The most recent short interest data has been released for the 06/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover."...
PFE: 36.30 (+0.06)
Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis
BusinessWire - Wed Jul 13, 7:00AM CDT
Pfizer Inc. (NYSE
FE) announced today the publication of findings from two pivotal Phase 3 studies of investigational crisaborole topical ointment 2% (formerly AN2728) in the online issue of the Journal of the American Academy of Dermatology. PFE: 36.30 (+0.06)
Sucampo to Stop Developing Cobiprostone for Oral Mucositis
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:28PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) announced that it will discontinue the development of its pipeline candidate, cobiprostone.
JNJ: 122.89 (-0.03), PFE: 36.30 (+0.06), SCMP: 11.37 (+0.04)
Shire's (SHPG) Dry Eye Disease Drug Xiidra Gets FDA Nod
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:20PM CDT
Shire plc (SHPG) received a major boost when the FDA approved its ophthalmology drug Xiidra for the treatment of the signs and symptoms of dry eye disease in adults.
JNJ: 122.89 (-0.03), SHPG: 193.07 (-2.24), PFE: 36.30 (+0.06)
Lower-cost biotech drug gets thumbs up from FDA panel
By MATTHEW PERRONE - AP - Tue Jul 12, 4:39PM CDT
WASHINGTON (AP) — The second-biggest selling drug in the world could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat rheumatoid arthritis and other inflammatory diseases.
JNJ: 122.89 (-0.03), PFE: 36.30 (+0.06), AMGN: 160.90 (-1.06)
JNJ VS. PFE: Which Is The Better Large Cap Pharma Stock?
Adam Clark - Zacks Investment Research - Mon Jul 11, 12:06PM CDT
Operating in an industry ranked in the top 10% of all industries by Zacks and both stocks sporting a Zacks Rank #2 (Buy), Johnson&Johnson and Pfizer Inc. should both be getting looked at from investors right now, but which is the better buy?
JNJ: 122.89 (-0.03), PFE: 36.30 (+0.06)
Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:23AM CDT
Pfizer Inc. (PFE) announced positive results from the phase III study, S-TRAC, on kidney cancer drug Sutent.
ABT: 42.01 (-0.46), PFE: 36.30 (+0.06), EXEL: 8.13 (-0.01), NVS: 82.08 (+0.40)
Shire (SHPG) Gets EU Nod for Label Expansion of Revestive
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:36PM CDT
Shire plc (SHPG) announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population.
ABT: 42.01 (-0.46), JNJ: 122.89 (-0.03), SHPG: 193.07 (-2.24), PFE: 36.30 (+0.06)
Roche Asthma Drug Xolair Gets FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:23PM CDT
Roche Holding AG (RHHBY) announced that the FDA has approved a label expansion of respiratory drug, Xolair.
JNJ: 122.89 (-0.03), PFE: 36.30 (+0.06), NVS: 82.08 (+0.40)
Alnylam (ALNY) Begins Phase I/II Study on Chronic HBV Drug
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 10:34AM CDT
Alnylam Pharmaceuticals (ALNY) announced that it has started a phase I/II study on ALN-HBV for the treatment of chronic hepatitis B virus infection.
ALNY: 63.19 (-0.81), INVA: 11.89 (+0.13), PFE: 36.30 (+0.06), BMY: 76.71 (+0.51)
Puma (PBYI) Stock Up, Phase II Data on Neratinib Published
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 10:28AM CDT
Puma Biotechnology (PBYI) reported the publication of phase II study (I-SPY 2) data on neratinib for the neoadjuvant treatment of breast cancer.
INVA: 11.89 (+0.13), PFE: 36.30 (+0.06), PBYI: 32.72 (-1.44)
Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT(R) (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma
BusinessWire - Fri Jul 08, 7:00AM CDT
Pfizer Inc. (NYSE
FE) today announced that the S-TRAC clinical trial (Sunitinib Trial in Adjuvant Renal Cancer), a Phase 3 study of SUTENT versus placebo in the adjuvant setting, met its primary endpoint of improving disease-free survival (DFS) as determined by blinded independent central review in patients with renal cell carcinoma (RCC) who are at high risk for recurrence after surgery. The S-TRAC trial is the first RCC trial of a tyrosine kinase inhibitor (TKI) to prolong DFS in the adjuvant setting. The concept of adjuvant therapy is to help lower the risk of cancer recurrence in patients with early-stage cancer. PFE: 36.30 (+0.06)
Seattle Genetics/Takeda Adectris' Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:21PM CDT
Seattle Genetics, Inc. (SGEN) announced that its partner Takeda Pharmaceutical Company Limited (TKPYY) has received marketing authorization for the label expansion of its lymphoma drug, Adcetris.
JNJ: 122.89 (-0.03), SGEN: 41.45 (-1.09), PFE: 36.30 (+0.06)
Merck KGaA/Pfizer Avelumab in JAVELIN Ovarian 100 Study
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:54PM CDT
Merck (MKGAF) and Pfizer (PFE) initiated JAVELIN Ovarian 100 on avelumab, in combination with platinum-based chemotherapy, for the treatment of ovarian cancer.
GWPH: 92.58 (-4.52), UTHR: 109.87 (-3.06), PFE: 36.30 (+0.06)
Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:09AM CDT
Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.
INVA: 11.89 (+0.13), PFE: 36.30 (+0.06), SNY: 42.04 (-0.46), REGN: 366.21 (-2.54)
Bristol-Myers Buys Cormorant, Focus on Immuno-Oncology
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:02AM CDT
Bristol-Myers (BMY) acquires a privately held pharma company, Cormorant Pharmaceuticals, to bolster its immuno-oncology pipeline.
INVA: 11.89 (+0.13), PFE: 36.30 (+0.06), BMY: 76.71 (+0.51)
Abbott Labs' Absorb Stent Gets Regulatory Approval in U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 8:58AM CDT
Abbott Laboratories (ABT) received a major boost when the FDA approved its bioresorbable heart stent, Absorb, for the treatment of coronary artery disease in the U.S.
ABT: 42.01 (-0.46), JNJ: 122.89 (-0.03), PFE: 36.30 (+0.06), STJ: 80.62 (-0.26)
Pfizer agrees to note addiction risks in opioid marketing
By JASON KEYSER - AP - Wed Jul 06, 1:48PM CDT
CHICAGO (AP) — The city of Chicago and Pfizer announced an agreement Wednesday committing the drugmaker to disclosing the serious risks of addiction in its marketing of prescription opioid painkillers.
PFE: 36.30 (+0.06)
